Business Standard

Strides Arcolab jumps on USFDA nod

Stock up 3% at Rs 923

Image

SI Reporter Mumbai

Strides Arcolab has jumped 3% in noon trades following USFDA nod for 2 ANDAs.

The company's wholly owned subsidiary - Onco Therapies, has secured approval for 2 oncology products from the United States Food and Drug Administration. The combined market for the two drugs in the United States is approximately $20 million.

Shares of Strides Arcolab opened at Rs 906 and surged to a high of Rs 933 in late-morning deals. The stock is currently up 3% at Rs 923. Around 68,000 shares have been traded on the BSE so far, as against a two week average of 39,000 shares.

The company is also scheduled to announce its third quarter FY13 results today.

 

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Oct 19 2012 | 12:08 PM IST

Explore News